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Lipiodol is an iodinated derivative of poppy seed oil, containing
ethyl esters of linoleic, oleic, palmitic and stearic acids, with an
iodine content of 38–40% wv (as a naturally iodinated compound)
(ABPI, 1991–92; BP, 1993; Chatin and Bonnrmain, 1992).
Lipiodol was first shown to be selectively taken up and retained by
primary hepatocellular carcinoma in 1979 (Nakakuma et al, 1979),
and hepatic metastases of colonic and neuroendocrine tumours in
1988 (Bretagne et al, 1988). This phenomenon of uptake and
retention has been used to deliver targeted therapies via the hepatic
artery to these tumours (Konno et al, 1983; Nakakuma et al, 1983;
Bretagne et al, 1988), either conjugating Lipiodol to cytotoxic
agents (such as Epirubicin) to give targeted chemotherapy, or by
radiolabelling some of the iodine in Lipiodol with 131I to deliver
targeted radiotherapy (Konno et al, 1983; Bretagne et al, 1988;
Novell et al, 1991; Vetter et al, 1991; Al-Mufti et al, 1995).
However, the results of clinical trials of its therapeutic value have
been unpredictable and rather disappointing (Friedman, 1983;
Madden et al, 1993). Several reasons have been given for such
poor results, including the lack of in vitro studies of the stability
and efficacy of such targeted therapies prior to their clinical use.
Our group have previously reported the in vitro selective uptake
and retention of Lipiodol by primary and metastatic hepatic malig-
nancy (Al-Mufti et al, 1995). In this study, an in-vitro assessment
of  131I-Lipiodol was made by studying its cytotoxicity against
primary liver and colorectal metastatic cancer cell lines, to investi-
gate the mechanism of action and the therapeutic effect of
Lipiodol-targeted therapy.
From our previous studies, in vitro uptake of Lipiodol is at its
maximum at 24 h after exposure, and the mean cell cultures
doubling time is 19 h (range 18–22 h). Accordingly, the in vitro
cytotoxicity in this study was assessed over a period of 48 h.
MATERIALS AND METHODS
Cell cultures
The malignant cell lines used were Hep-G2 (human hepatoma),
LoVo (human colorectal hepatic cancer) and SW620 (human
colorectal metastatic cancer). Control non-malignant cells were
HUVEC (human umbilical vein endothelial cells). Other non-
malignant control cell lines were not readily available for assess-
ment. The cancer cell lines were obtained from the European
Collection of Animal Cell Cultures, Porton Down, Salisbury,
Wiltshire SP4 0JG, UK.
The culture medium for Hep-G2
The standard medium recommended by the source laboratory was
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
calf serum (FCS), L-glutamine 2 mM l-1, penicillin 100 000 units l
and streptomycin 100 mg l-1; pH at 7.
The culture medium for LoVo
The standard medium recommended by the source laboratory was
Hams F12 or DMEM with 10% FCS, L-glutamine 2 mM l-1,
penicillin 100 000 units l-1 and streptomycin 100 mg l-1.
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The standard medium recommended by the source laboratory was
Leibovitz L15 medium with 10% FCS, L-glutamine 2 mM l-1,
penicillin 100 000 units l-1 and streptomycin 100 mg l-1.
ECCM-culture medium for HUVEC
M199 medium, 20% FCS, NaHCO3, glutamine, heparin, penicillin
and streptomycin; pH 7.2 to 7.3; filtered17.
Method for culturing the cancer cell lines
The cancer cell lines (Hep-G2, SW620 and LoVo) were supplied
in a cryotube frozen in liquid nitrogen. The cryotube was left at
room temperature for 1 min, then transferred to 37°C waterbath
for 2 min. The cells in the cryotube were thawed, decanted into a
sterile universal with 10 ml of medium (at 4°C) and centrifuged at
90 g for 7 min. The cell pellet was re-suspended with pre-warmed
culture medium (Dulbecco’s modified Eagle’s medium, DMEM),
cultured in a vented 25 mm2 flask and incubated with 5% carbon
dioxide humid atmosphere at 37°C. At 90% confluence, the cells
were subcultured by discarding the old medium, washing with
phosphate-buffered saline (PBS) less Ca2+/Mg2+ and then
trypsinizing the monolayer with trypsin–EDTA (´ 1), for 5–10
min, until the cells were detached. The cells were then suspended
in culture medium, centrifuged at 90 g for 5 min and then subcul-
tured in 96-well plates, seeded at 1 ´ 104 cells per well, and incu-
bated overnight at 37°C at 5% carbon dioxide (CO2) and humidity.
The cultures were examined 24 h before starting the radioisotope
experiment (Leibovitz et al, 1976; Drewinko et al, 1976; Knowles
et al, 1980). The mean cell culture doubling times for Hep-G2 and
LoVo was 19 h (range 18–20) and for SW620 was 20 h (range
19–21). Full aseptic precautions were used with the cell cultures.
Method for culturing HUVEC
A fresh umbilical cord was collected from the labour ward in a
sterile container with 200 ml of M199 medium and 10% NBCS
(new born calf serum). Ethical approval from the Obstetric Unit
was obtained. The cord was examined for any damage or clamp
marks, selecting a suitable 20 cm segment for culture. The two
ends of the umbilical vein were cannulated with a size 16 or 18 F
tube and the tubes were secured with silk ties. The vein was
flushed with PBS solution (less Ca2+/Mg2+), to remove any blood
clots, and to detect any leaks. Collagenase 0.1% solution (15 ml)
was then injected into the vein and it was incubated at 37°C for
5 min. The collagenase solution was then decanted into a sterile
container. An equal volume of M199–20% NBCS was added
to neutralize the collagenase, and the suspended cells were
centrifuged at 300 g for 5 min. The cells in the pellet were re-
suspended with endothelial cell culture medium (ECCM), cultured
in vented flasks (25 mm2) and incubated at 37°C with 5% CO2
humid atmosphere. At 24 h the cultures were washed with 5 ml of
M199 medium to remove dead cells and red blood cells, and then
the cells were fed with fresh ECCM every 48 h and incubated at
37°C with 5% CO2 and humidity.
When a 90% confluent cell monolayer was reached, the cells
were subcultured by discarding the old medium, washing the
monolayer with PBS (less Ca2+/Mg2+) and then trypsinizing the
culture with trypsin-EDTA (´ 1) for 3–5 min at 37°C, until cells
were detached. The enzyme was then partially neutralized by the
addition of 20% NBCS in M199 medium, and the cell suspension
was centrifuged at 300 g for 5 min. Cell counts and viability were
determined by trypan blue exclusion using a haemocytometer. The
cells in the pellet were resuspended in 100 ml of ECGS (endo-
thelial cell growth supplement) and culture medium (ECCM). The
cells were subcultured in 96-well plates, seeded at 1 ´ 104 per well
and incubated at 37°C with 5% CO2 and humidity, and left
overnight to settle. The cultures were examined 24 h before
starting the radioisotope experiment (Jaffe et al, 1973; Jaffe,
1987). The mean cell culture doubling time for HUVEC was
20.5 h (range 19–22).
Radioisotopes
131I-Lipiodol used in this study was supplied by CIS in France (via
CIS [UK] Limited, Dodding House, Wellington Road, High
Wycombe HP12 3PR, UK), which was identical to the 131I-
Lipiodol used therapeutically. The radioactive dose of Iodine 131
(131I) used was according to a dose-titration method as shown
below.
General method
Each of the cell lines were subcultured in 96-well plates; cells
were seeded at 1 ´ 104 cells per well. The cell cultures were
allowed to grow overnight in a humidified incubator with an
atmosphere of 5% CO2 at 37°C. At 24 h (zero hour), the old
medium was discarded and replaced with control or radioisotope
culture medium according to the appropriate concentration and
radioactivity, and the cultures were then allowed to grow for a
further period of up to 48 h. Lipiodol was emulsified with diatri-
zoate (urografin) into an aqueous-based emulsion, similar to the
standard clinical use of urografin prior to the arterial administra-
tion of Lipiodol. The cell cultures were treated as follows:
1. 100 ml medium in each of the control wells (first control), with
culture medium only.
2. 100 ml cold-Lipiodol medium (4%) in each of the Lipiodol
control wells (second control).
3. 100 ml of plain 131I 40 mCi ml-1 in each of the radioactive
control wells (third control).
4. 100 ml of the 131I-Lipiodol 10 mCi ml-1 emulsion in each of the
I131 low-dose wells (equivalent to 4% Lipiodol).
5. 100 ml of the 131I-Lipiodol 20 mCi ml-1 emulsion in each of the
I131 medium-dose wells (= 4% Lipiodol). This is equivalent to
the radio-therapeutic clinical dose.
6. 100 ml of the 131I-Lipiodol 40 mCi ml-1 emulsion in each of the
I131 high-dose wells (equivalent to 4% Lipiodol).
The cultures were incubated at 37°C with 5% CO2 for 48 h in a
special shielded (radioisotope) room under full radiation protec-
tion control. The experiment was repeated three times with four
sets of plates for each cell line, each containing six identical wells
for each test dose of radioactivity. At the end of the incubation
period, the control and radioactive culture media were discarded
appropriately and the cell monolayers were washed with PBS
solution three times. One set of the plates was then processed for
cell density and viability using the sulphorhodamine B (SRB)
assay (Skehan et al, 1990). Another set of the plates was processed
for measurement of cellular radioactivity using a gamma scintilla-
tion counter (Pharmacia, 1470 Wizard). The 96-well plates were
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selected mode of radioactivity for 131I after calibration, and a
computerized readout was obtained. Cell viability and counts were
further assessed with the standard trypan blue exclusion method
using the haemocytometer. After trypsinization, the cells were
suspended in medium, and the cell count was calculated for each
well. Nine readings were calculated per well and the mean value
was obtained. The total cell count was calculated by multiplying
the mean result by the total volume in which the cells were
suspended. Light and electron microscopy examinations were also
used to assess cytotoxicity and uptake of radioactivity.
Method for the sulphorhodamine B (SRB) test
This test was used to measure cell density after treatment, by using
protein analysis. At the end of the experiment (exposure to
Lipiodol-targeted radiotherapy 1667
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Figure 1 Effects of 131I-Lipiodol on the cell growth of Hep-G2 hepatoma cell
line, compared to control Lipiodol and control 131I. Similar effects were seen
in other cancer cell lines. *P < 0.0001 compared to controls. Control, — l —;
Lipiodol control, — n —; Control 131I (40 mCi ml-1), – .P. –; 131I-Lipiodol
(10 mCi ml-1), – u –; 131I-Lipiodol (20 mCi ml-1), – n –; 131I-Lipiodol
(40 mCi ml-1), – P –
Figure 2 Effects of 131I-Lipiodol on the cell growth of non-malignant
endothelial cells (HUVEC). *P < 0.00001, **P = 0.04 compared to controls.
Control,  – l –; Lipiodol control, — n —; Control 131I (40 mCi ml-1), – .P.– ;
131I-Lipiodol (10 mCi ml-1), – u –; 131I-Lipiodol (20 mCi ml-1), — n —;
131I-Lipiodol (40 mCi ml-1), – .P.–
Table 2 Effects of 131I-Lipiodol on LoVo (human colorectal hepatic cancer) at 48 h
LoVo cell line Mean d.p.m. counts Mean cell counts (´ 103) Viable cells
n = 6 (s.d.) (gamma counter) (haemocytometer) (trypan blue) (%)
Control wells 195.7 (29.1) 57.5 (5.8) 97.2
4% Lipiodol control wells 182.7 (41.8) 53.1 (8.2) 97.5
Plain I131 (40 mCi ml-1) 591.1 (30.3) 55.6 (6.3) 98.1
Low-dose 131I-Lipiodol (10 mCi ml-1) 6317.6 (44.9) a16.3 (3.4) a6.0
Medium-dose 131I-Lipiodol (20 mCi ml-1) 13 421.2 (46.2) a12.1 (2.9) a4.2
High-dose 131I-Lipiodol (40 mCi ml-1) 22 161.3 (41.5) a7.1 (2.3) a2.4
n = 6; d.p.m. = disintegration per minute; standard deviation in parentheses. Number of cells at the start of experiment was 10 ´ 103
cells per well. aP-value = < 0.001.
Table 1 Effects of 131I-Lipiodol on Hep-G2 (human hepatoma) at 48 h
Hep-G2 cell line Mean d.p.m. counts Mean cell counts (´ 103) Viable cells
n = 6 (s.d.) (gamma counter) (haemocytometer) (trypan blue) (%)
Control wells 191.9 (21.3) 45 (3.1) 98.1
4% Lipiodol control wells 211.7 (34.5) 41.3 (7.1) 97.6
Plain I131 (40 mCi ml-1) 365.2 (26.7) 38.1 (3.8) 97.8
Low-dose 131I-Lipiodol (10 mCi ml-1) 2566.3 (51.3) a8.1 (2.7) *4.7
Medium-dose 131I-Lipiodol (20 mCi ml-1) 5565.9 (44.8) a5.6 (1.8) *3.2
High-dose 131I-Lipiodol (40 mCi ml-1) 17 362.1 (47.2) a4 (1.5) *1.9
n = 6; d.p.m. = disintegration per min; standard deviation in parentheses. Number of cells at the start of experiment was 10 ´ 103 cells
per well. aP-value = < 0.0001.radioisotopes or controls), the medium was discarded and the
wells were rinsed with PBS and the cells were then exposed to
100 ml of cold 10% wv trichloroacetic acid for 1 h at 4°C. The
plates were then washed with water and air dried. The SRB assay
was commenced by dissolving 0.4% wv SRB in 1% acetic acid
and adding 100 ml to each well to stain the fixed cells for 30 min.
The dye was then removed and immediately rinsed with 1% acetic
acid four times and then air dried. The assay reading was
commenced by solubilizing the bound dye with 100 ml 10 mM
(0.121 g 100 ml-1) Tris base, pH 10.5, for 15 min on a gyratory
shaker. The cell density was calculated for each culture using a 96-
well plate reader at 490 nm (Skehan et al, 1990).
RESULTS
Using previously described method, Lipiodol uptake by all the
cancer cell lines and by the endothelial cells was demonstrated on
light and electron microscopy as early as 3 h (Al-Mufti et al,
1996). In this study, 131I-Lipiodol was also demonstrated within the
cancers cells and the benign endothelial cells as early as 6 h.
Lipiodol alone as a control (without 131I) had no effect on the cell
growth or viability when compared to the controls, and was there-
fore not cytotoxic to any of the cell lines used in this study. At
early stages of exposure, there were no cytotoxic effects seen as
expected.
131I-Lipiodol was found to be highly cytotoxic against all the
three malignant cell lines (Hep-G2, LoVo and SW620) at the 
low-, medium- and high-dose range (P = 0.0001, Figure 1). The
cytotoxicity effects of 131I-Lipiodol increased with increasing
doses of radioactivity, with optimal toxicity being achieved with
the high-dose (40 mCi ml-1). The results are summarized in Tables
1–4. The effects of 131I-Lipiodol on Hep-G2, LoVo and SW620
were identical, and the cytotoxicity was maximal at 48 h of expo-
sure. 131I-Lipiodol was not cytotoxic to endothelial cells (Figure 2,
Table 4) but did reduce the rate of cell growth (cytostatic
effect). The percentage of endothelial cell viability remained
high (87–93%) after exposure to the three different doses of
131I-Lipiodol, compared to 96% cell viability in the control
cultures.
131I alone did not have any cytotoxic effect against any of the
cell lines used (malignant and non-malignant cells), even at high
dosage (40 mCi ml-1) despite the cells being in direct contact with
the radioiodine (Figures 1 and 2). In fact the cell growth and count
of the control endothelial cells was slightly higher after exposure
to 131I alone, and all the cultures (malignant and non-malignant)
maintained a high percentage of cell viability (97–98%).
Light and electron microscopy confirmed the uptake of Lipiodol
in the form of cytoplasmic membrane-bound vesicles in all the cell
lines (malignant and non-malignant) as illustrated in Figure 3A.
Electron microscopy also confirmed the uptake of 131I-Lipiodol by
1668 RAM Al-Mufti et al
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Table 3 Effects of 131I-Lipiodol on SW620 (human colorectal metastatic cancer) (48 h)
SW20 cell line Mean d.p.m. counts Mean cell counts (´ 103) Viable cells
n = 6 (s.d.) (gamma counter) (haemocytometer) (trypan blue) (%)
Control wells 176.4 (20.8) 48.8 (3.2) 96.2
4% Lipiodol control wells 164.5 (32.1) 48.1 (5.4) 95.3
Plain I131 (40 mCi ml-1) 266.4 (37.4) 52.5 (3.9) 97.1
Low-dose 131I-Lipiodol (10 mCi ml-1) 5334.8 (46.3) a15.6 (2.8) a5.2
Medium-dose 131I-Lipiodol (20 mCi ml-1) 14 973.1 (39.7) a8.9 (3.3) a2.8
High-dose 131I-Lipiodol (40 mCi ml-1) 26 712.1 (43.2) a3.9 (1.1) a1.4
n = 6; d.p.m. = disintegration per minute; standard deviation in parentheses. Number of cells at the start of experiment was 10 ´ 103
cells per well. aP-value = < 0.0001.
Table 4 Effects of 131I-Lipiodol on HUVEC (human umbilical vein endothelial cells) (48 h)
HUVEC cell line Mean d.p.m. counts Mean cell counts (´ 103) Viable cells
n = 6 (s.d.) (gamma counter) (haemocytometer) (trypan blue) (%)
Control wells 144.2 (39.2) 40.3 (3.4) 95.8
4% Lipiodol control wells 176.4 (45.7) 39.4 (6.2) 97.1
Plain I131 (40 mCi ml-1) 375.9 (52.2) 41.4 (4.7) 98.2
Low-dose 131I-Lipiodol (10 mCi ml-1) 8844.9 (48.3) b35.9 (3.1) b85.4
Medium-dose 131I-Lipiodol (20 mCi ml-1) 9202.2 (53.2) a18.9 (3.2) b84.7
High-dose 131I-Lipiodol (40 mCi ml-1) 9023.1 (46.8) a12.8 (2.5) b80.4
n = 6; d.p.m. = disintegration per minute; standard deviation in parentheses. Number of cells at the start of experiment was 10 ´ 103
cells per well, a P-value = < 0.0001, bP-value = 0.04.all the cells and the cytotoxic effects of 131I-Lipiodol on the cancer
cell lines (Figure 3B). There was 100% cell death at 48 h, leaving
cell shadows and cytoskeletons of dead cancer cells still
containing  131I-Lipiodol vesicles (Figure 3B). In contrast, electron
microscopic study of the non-malignant control endothelial cells
confirmed the high percentage of cell viability (percentage of
viable cells 80–85%) at 48 h of exposure to 131I-Lipiodol, in spite
of its uptake by the endothelial cells, as illustrated in Figure 4.
Sulphorhodamine B test and gamma scintillation counting
(Table 5) correlated well with the cell growth curves, cell viability
assays and electron microscopy. All the cell lines showed high
cellular radioactivity following exposure to 131I-Lipiodol, but the
Lipiodol-targeted radiotherapy 1669
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Table 5 The sulphorhodamine B (SRB) test for cell density assay (48 h)
Cell density measurements using the sulforhodamine B assay
Cell lines Control Lipiodol 131I control 131I-Lipiodol 131I-Lipiodol 131I-Lipiodol
control 10 mCi ml-1 20 mCi ml-1 40 mCi ml-1
Hep-G2 0.074 0.071 0.069 0.013* 0.010* 0.002*
LoVo 0.049 0.054 0.048 0.015* 0.012* 0.006*
SW620 0.039 0.036 0.037 0.007* 0.003* 0.002*
HUVEC 0.044 0.039 0.049 0.036 0.042 0.050
n = 6; results are the mean absolute absorbance values for the cell density index. aP-value = < 0.001.
A
B
A
B
Figure 3 Electron micrographs of Hep-G2 cancer cells. (A) Healthy cells
with cytoplasmic Lipiodol in membrane-bound vesicles, following exposure to
control Lipiodol. (B) 131I-Lipiodol particles inside the dead cancer cells,
following exposure to 131I-Lipiodol
Figure 4 Electron micrographs of HUVEC endothelial cells. (A) Healthy
cells with cytoplasmic membrane-bound vesicles of lipid, following exposure
to control Lipiodol. (B) 131I-Lipiodol particles inside the healthy benign cells,
following exposure to 131I-Lipiodolradioactivity remained low following exposure to 131I alone,
without Lipiodol (Tables 1–4). This confirmed that Lipiodol
was essential for transporting 131I into the cells to achieve its
preferential cytotoxicity effects in the malignant cells (i.e. intra-
cellular radiotherapy).
DISCUSSION
This study confirms that the uptake of Lipiodol is not specific to
cancer cell lines, as the non-malignant endothelial cells take up
Lipiodol as well. However, 131I-Lipiodol is selectively and highly
cytotoxic against all the cancer cell lines but not against the benign
endothelial cells. Although the mechanism of Lipiodol uptake is
poorly understood, this study confirms our previous reports that
Lipiodol is taken up and is retained in the form of cytoplasmic
membrane-bound vesicles (Al-Mufti et al, 1995). Quantification
methods using computer-assisted image analysis of the uptake of
Lipiodol by the malignant and the non-malignant cell lines
(Al-Mufti et al, 1996) have revealed that cancer cell lines, unlike
non-malignant cells, are unable to expel Lipiodol. This may
further enhance the cytotoxic effect of 131I-Lipiodol in cancer cells.
Lipiodol alone does not appear to have any cytotoxic effect
against any of the cell lines studied. This confirms the clinical
observations seen in many in vivo studies of Lipiodol-targeted
therapies of liver cancers. It is noteworthy that, in this study, 131I
alone without the Lipiodol has no cytotoxic effect against any of
the cell lines tested. This is in spite of the cell cultures being
exposed directly to a high and comparable dose of 131I radio-
activity in their culture medium (extracellular radiation). This is
the first study to show the importance of using Lipiodol to deliver
131I, by virtue of its ability to deliver the isotope inside the cancer
cells (intracellular radiotherapy), even if in membrane-bound vesi-
cles. There is no separation of the 131I from Lipiodol during the
process of uptake by the cancer cells, as Lipiodol is a naturally
iodinated oil compound, with an iodine content of 38–40%. 131I-
Lipiodol shows cytotoxic effects against the cancer cell lines even
when the radioactive dose is very small, a quarter of the radioac-
tivity of the 131I alone.
The morphological changes observed with light and electron
microscopy, following 131I-Lipiodol administration, confirmed
intracellular  131I-Lipiodol vesicles inducing acute cell death of
cancer cells, with maximum effect seen at 24 and 48 h, with little
effects at the early stages of exposure (3 and 6 h) as expected.
However, the effects on the non-malignant endothelial cells were
only cytostatic, giving a reduction in the rate of cell growth, but a
high percentage viable cells. This mechanism may operate in vivo
when Lipiodol-targeted therapies are used. The long-term apop-
totic effects of 131I-Lipiodol on the control endothelial cells were
not evaluated further in this study.
As Lipiodol is a naturally iodized oil with a higher density
than the aqueous culture media, one could argue that by leaving
the culture media incubated for 48 h inside the incubator, the
131I-Lipiodol component of the emulsion could then separate and
sink into the bottom of the wells and would come into intimate
contact with cell monolayers at the base of the wells. However,
it is unlikely that this had any significant effect on the results in
this study for three reasons. Diatrizoate (urografin) was used to
emulsify the Lipiodol (as it is commonly used clinically prior to
the arterial administration, which would maintain the 131I-Lipiodol
in its suspended form much longer), together with the use of
human endothelial cells as benign control cells and the use of
much smaller doses of 131I-Lipiodol to compare to that of 131I alone
(down to a quarter of the radioactive dose of 131I). If the
131I-Lipiodol were to sink down to the bottom of the wells, then
one would expect that not only the cancer cells, but all the
endothelial cells, to be killed because of the intimate contact with
a high dose of radioactivity. There was a significant cytotoxic
effect seen with the use of even a low dose of 131I-Lipiodol
(0.01 mCi ml-1), compared to a much higher dose of radioactivity
with131I alone (0.04 mCi ml-1), which had no cytotoxic effect.
The use of the radioactive form of Lipiodol as a potentially
effective treatment for patients with hepatocellular carcinoma and
some colorectal hepatic metastases is supported by the effective
localization and retention of Lipiodol by human hepatocellular and
colorectal metastatic cancers in vitro. The results of 131I-Lipiodol
cytotoxicity in Hep-G2, LoVo and SW620 in this study indicate
that 131I-Lipiodol is highly cytotoxic to such tumours that show
good uptake of Lipiodol, and that the radiation lethal dose can be
as low as 0.01 mCi ml-1 in cell cultures, with a steep dose–response
relationship. Lipiodol-targeted radiotherapy would have a limited
effect against tumours that show poor Lipiodol uptake.
Hepatocellular carcinoma and metastatic colorectal cancers have
been regarded as resistant to radiotherapy, but this study has
shown that these tumours may be sensitive to intracellular radio-
therapy with 131I-Lipiodol. This is particularly significant, since
highly effective cytotoxic dosages of 131I-Lipiodol can be admini-
stered intra-arterially quite safely in patients with these liver
cancers with minimal cytotoxicity to the normal liver (Raoul et al,
1988). The only limiting factor for Lipiodol-targeted radiotherapy,
as seen in the clinical trials, is the variability of the in vivo uptake
of Lipiodol by cancer cells. This is dependent on the intra-arterial
delivery of Lipiodol to the cancer. If the tumour uptake of Lipiodol
can be improved, then better cytotoxic effects of Lipiodol-targeted
radiotherapy should be achieved. Future clinical studies should be
directed towards improving the in vivo uptake of Lipiodol, for
example by combining this form of targeted therapy with vaso-
active agents such as angiotensin.
In conclusion, in vitro cytotoxicity assay of 131I-Lipiodol
revealed it to be cytotoxic against cells taken from human hepato-
cellular carcinoma and colorectal metastatic cancers but not to
benign endothelial cells. This was related to the selective uptake
and retention of Lipiodol by the cancer cell lines, with evidence of
intra-cytoplasmic accumulation of 131I-Lipiodol (intracellular
radiation). Equivalent or higher doses of radioactivity delivered to
the cells in the absence of Lipiodol (i.e. extracellular radiation)
had no toxic effect.
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